Open Access

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - CON

Congress Session

About the speaker

Professor Samuel Viskin

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)
7 presentations
0 follower

11 more presentations in this session

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - PRO

Speaker: Professor V. Probst (Nantes, FR)

Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal PRO

Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal CON

Thumbnail

Chairperson conclusion & Closing question

Thumbnail

Access the full session

Controversies in channelopathy

Speakers: Professor S. Viskin, Professor V. Probst
Thumbnail

About the event

Image

EHRA 2018

18 March - 20 March 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk